Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and...
Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq ® ), ...
Novocure to launch Optune Lua in Japan with national reimbursement coverage
Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph Brackmann,...
Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax ® approved by the U.S. FDA for the...
British Columbia becomes first Canadian province to provide coverage for TTFields therapy for eligible glioblastoma patients
Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3...
Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Novocure to present at the 44 th Annual...
Novocure (NASDAQ: NVCR) announced today that management will participate in the 44 th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank...